Doximity Faces Continued Softness in Pharma Marketing Spending, RBC Capital Markets Says

MT Newswires Live06-25

Doximity (DOCS) expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.

The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.

The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.

RBC has an outperform rating on the stock and a $28 price target.

Shares of Doximity were down 3.5% in Thursday trading.

Price: 20.11, Change: -0.72, Percent Change: -3.46

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2646804828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646804828","market":"us","top_or_hot":-1,"title":"Doximity Faces Continued Softness in Pharma Marketing Spending, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> Doximity (DOCS) expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.</p><p>The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.</p><p>The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.</p><p>RBC has an outperform rating on the stock and a $28 price target.</p><p>Shares of Doximity were down 3.5% in Thursday trading.</p><p>Price: 20.11, Change: -0.72, Percent Change: -3.46</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Doximity Faces Continued Softness in Pharma Marketing Spending, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoximity Faces Continued Softness in Pharma Marketing Spending, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-25 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Doximity (DOCS) expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.</p><p>The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.</p><p>The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.</p><p>RBC has an outperform rating on the stock and a $28 price target.</p><p>Shares of Doximity were down 3.5% in Thursday trading.</p><p>Price: 20.11, Change: -0.72, Percent Change: -3.46</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0128525929.USD","symbol_name":"TEMPLETON GLOBAL \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2646804828","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646804828","pubTimestamp":1782401288,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Doximity  expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.RBC has an outperform rating on the stock and a $28 price target.Shares of Doximity were down 3.5% in Thursday trading.Price: 20.11, Change: -0.72, Percent Change: -3.46","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4207":"综合性银行","DOCS":"Doximity, Inc.","BK4539":"次新股","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","BK4551":"寇图资本持仓","BK4588":"碎股","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","BK4613":"AI应用软件","BK4585":"ETF&股票定投概念","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4167":"医疗保健技术"},"translate_title":"加拿大皇家银行资本市场表示，Doximity面临医药营销支出持续疲软的问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DOCS":1.5},"content_text":"Doximity (DOCS) expects continued softness in pharmaceutical marketing spending through at least fiscal Q1 and Q2, while it will likely benefit from some artificial intelligence revenue contribution in fiscal Q3, RBC Capital Markets said in a note Wednesday.The brokerage, which hosted investor meetings with the company, said it came away cautious on the company's near-term outlook, but noted greater visibility on opportunities for revenue growth toward H2 of fiscal 2027 and more materially into fiscal 2028 from capturing more spend into its AI tools.The company believes its AI offering is better positioned with large pharmaceutical partners seeking alternatives to programmatic, biddable advertising models, according to the note.RBC has an outperform rating on the stock and a $28 price target.Shares of Doximity were down 3.5% in Thursday trading.Price: 20.11, Change: -0.72, Percent Change: -3.46","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"economic","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646804828","isCrawlerRequest":true}